{Reference Type}: Journal Article
{Title}: The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.
{Author}: Ziętara KJ;Wróblewska K;Zajączkowska M;Taczała J;Lejman M;
{Journal}: Int J Mol Sci
{Volume}: 25
{Issue}: 13
{Year}: 2024 Jun 21
{Factor}: 6.208
{DOI}: 10.3390/ijms25136844
{Abstract}: B-cell lymphoblastic leukemia is a hematologic neoplasm that poses a serious health concern in childhood. Genetic aberrations, such as mutations in the genes IL-7, IL7R, JAK1, JAK2, TLSP, CRLF2, and KTM2A or gene fusions involving BCR::ABL1, ETV6::RUNX1, and PAX5::JAK2, often correlate with the onset of this disease. These aberrations can lead to malfunction of the JAK-STAT signaling pathway, which is implicated in various important biological processes, including those related to immunology. Understanding the mechanisms underlying the malfunction of the JAK-STAT pathway holds potential for research on drugs targeting its components. Available drugs that interfere with the JAK-STAT pathway include fludarabine, ruxolitinib, and fedratinib.